Quantum Mechanics/Molecular Mechanics Modeling of Covalent Addition between EGFR-Cysteine 797 and N-(4-Anilinoquinazolin-6-yl) Acrylamide

Irreversible epidermal growth factor receptor (EGFR) inhibitors can circumvent resistance to first-generation ATP-competitive inhibitors in the treatment of nonsmall-cell lung cancer. They covalently bind a noncatalytic cysteine (Cys797) at the surface of EGFR active site by an acrylamide warhead. Herein, we used a hybrid quantum mechanics/molecular mechanics (QM/MM) potential in combination with umbrella sampling in the path-collective variable space to investigate the mechanism of alkylation of Cys797 by the prototypical covalent inhibitor N-(4-anilinoquinazolin-6-yl) acrylamide. Calculations show that Cys797 reacts with the acrylamide group of the inhibitor through a direct addition mechanism, with Asp800 acting as a general base/general acid in distinct steps of the reaction. The obtained reaction free energy is negative (ΔA = -12 kcal/mol) consistent with the spontaneous and irreversible alkylation of Cys797 by N-(4-anilinoquinazolin-6-yl) acrylamide. Our calculations identify desolvation of Cys797 thiolate anion as a key step of the alkylation process, indicating that changes in the intrinsic reactivity of the acrylamide would have only a minor impact on the inhibitor potency.

[1]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[2]  M. Karplus,et al.  A combined quantum mechanical and molecular mechanical potential for molecular dynamics simulations , 1990 .

[3]  Preston Moore,et al.  Metadynamics as a tool for exploring free energy landscapes of chemical reactions. , 2006, Accounts of chemical research.

[4]  R. Bednar,et al.  Reactivity and pH dependence of thiol conjugation to N-ethylmaleimide: detection of a conformational change in chalcone isomerase. , 1990, Biochemistry.

[5]  A. Y. Lu,et al.  Contributions of thiolate "desolvation" to catalysis by glutathione S-transferase isozymes 1-1 and 2-2: evidence from kinetic solvent isotope effects , 1991 .

[6]  Laura Legnani,et al.  Mechanism of falcipain-2 inhibition by α,β-unsaturated benzo[1,4]diazepin-2-one methyl ester , 2012, Journal of Computer-Aided Molecular Design.

[7]  R. Swendsen,et al.  THE weighted histogram analysis method for free‐energy calculations on biomolecules. I. The method , 1992 .

[8]  K. Gajiwala,et al.  Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. , 2013, Structure.

[9]  Jiali Gao,et al.  Methods and Applications of Combined Quantum Mechanical and Molecular Mechanical Potentials , 2007 .

[10]  Kate S Carroll,et al.  Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. , 2011, Nature chemical biology.

[11]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[12]  Matthew Meyerson,et al.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.

[13]  Hua Guo,et al.  Quantum mechanical/molecular mechanical and density functional theory studies of a prototypical zinc peptidase (carboxypeptidase A) suggest a general acid-general base mechanism. , 2009, Journal of the American Chemical Society.

[14]  R. Roskoski.  ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. , 2014, Pharmacological research.

[15]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[16]  M. Mor,et al.  Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. , 2008, Chemical communications.

[17]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[18]  Geoffrey R. Oxnard,et al.  Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer , 2013, Science Translational Medicine.

[19]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[20]  Ewa I. Chudyk,et al.  Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase , 2011, Journal of molecular modeling.

[21]  A. Cavalli,et al.  A Catalytic Mechanism for Cysteine N-Terminal Nucleophile Hydrolases, as Revealed by Free Energy Simulations , 2012, PloS one.

[22]  Chao Zhang,et al.  Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. , 2007, Nature chemical biology.

[23]  Ross C Walker,et al.  Implementation of the SCC-DFTB method for hybrid QM/MM simulations within the amber molecular dynamics package. , 2007, The journal of physical chemistry. A.

[24]  Lars Ridder,et al.  Quantum mechanical/molecular mechanical free energy simulations of the glutathione S-transferase (M1-1) reaction with phenanthrene 9,10-oxide. , 2002, Journal of the American Chemical Society.

[25]  M. Elstner.  The SCC-DFTB method and its application to biological systems , 2006 .

[26]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[27]  R. Benesch,et al.  The Acid Strength of the -SH Group in Cysteine and Related Compounds , 1955 .

[28]  Adrian J Mulholland,et al.  Mechanism of C-terminal intein cleavage in protein splicing from QM/MM molecular dynamics simulations. , 2012, Organic and biomolecular chemistry.

[29]  D. Gatti.  Biapenem Inactivation by B2 Metallo β-Lactamases: Energy Landscape of the Post-Hydrolysis Reactions , 2012, PloS one.

[30]  K. Gibson,et al.  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. , 2001, Bioorganic & medicinal chemistry letters.

[31]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[32]  K. Gold,et al.  Afatinib in the treatment of head and neck squamous cell carcinoma , 2014, Expert opinion on investigational drugs.

[33]  C. Klein,et al.  Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker , 2012, Journal of Pharmacology and Experimental Therapeutics.

[34]  B. Engels,et al.  Mechanistic Study of the Reaction of Thiol‐Containing Enzymes with α,β‐Unsaturated Carbonyl Substrates by Computation and Chemoassays , 2010, ChemMedChem.

[35]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[36]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[37]  Adrian J Mulholland,et al.  Modelling enzyme reaction mechanisms, specificity and catalysis. , 2005, Drug discovery today.

[38]  W. Denny,et al.  Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  G. Giaccone,et al.  A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib , 2014, Cancer.

[40]  Francesco Luigi Gervasio,et al.  From A to B in free energy space. , 2007, The Journal of chemical physics.

[41]  Adrian J Mulholland,et al.  "Lethal synthesis" of fluorocitrate by citrate synthase explained through QM/MM modeling. , 2011, Angewandte Chemie.

[42]  Bernard R Brooks,et al.  Exploring SCC-DFTB paths for mapping QM/MM reaction mechanisms. , 2007, The journal of physical chemistry. A.

[43]  L. Pustilnik,et al.  Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. , 1997, Cancer research.

[44]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[45]  G. Keating,et al.  Afatinib: First Global Approval , 2013, Drugs.

[46]  Juswinder Singh,et al.  Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. , 2013, Cancer discovery.

[47]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[48]  S. Sano,et al.  Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor , 2013, Oncogene.

[49]  Marco De Vivo,et al.  The increasing role of QM/MM in drug discovery. , 2012, Advances in protein chemistry and structural biology.

[50]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[51]  A. Warshel.  Computer simulations of enzyme catalysis: methods, progress, and insights. , 2003, Annual review of biophysics and biomolecular structure.

[52]  M. Mor,et al.  Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. , 2012, Biochemical pharmacology.

[53]  G. Colombo,et al.  Inactivation of TEM-1 by avibactam (NXL-104): insights from quantum mechanics/molecular mechanics metadynamics simulations. , 2014, Biochemistry.

[54]  Lars Ridder,et al.  Mechanisms of antibiotic resistance: QM/MM modeling of the acylation reaction of a class A beta-lactamase with benzylpenicillin. , 2005, Journal of the American Chemical Society.

[55]  M. Eck,et al.  Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. , 2010, Biochimica et biophysica acta.

[56]  K. Merz,et al.  Mechanistic insights into Mg2+-independent prenylation by CloQ from classical molecular mechanics and hybrid quantum mechanics/molecular mechanics molecular dynamics simulations. , 2014, Biochemistry.

[57]  Hua Guo,et al.  QM/MM studies of monozinc β-lactamase CphA suggest that the crystal structure of an enzyme-intermediate complex represents a minor pathway. , 2010, Journal of the American Chemical Society.

[58]  Adrian J Mulholland,et al.  Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450 , 2011, Proceedings of the National Academy of Sciences.

[59]  P. Kuzmič,et al.  Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance , 2013, Proceedings of the National Academy of Sciences.

[60]  A. Roitberg,et al.  Free energy study of the catalytic mechanism of Trypanosoma cruzi trans-sialidase. From the Michaelis complex to the covalent intermediate. , 2011, Biochemistry.

[61]  A. Ardizzoni,et al.  Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. , 2012, Journal of medicinal chemistry.

[62]  E. Kwak.  The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. , 2011, The oncologist.

[63]  W. Pao,et al.  Mechanism for activation of mutated epidermal growth factor receptors in lung cancer , 2013, Proceedings of the National Academy of Sciences.

[64]  Kirill Zinovjev,et al.  A Collective Coordinate to Obtain Free Energy Profiles for Complex Reactions in Condensed Phases. , 2012, Journal of chemical theory and computation.

[65]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[66]  M. Levitt,et al.  Theoretical studies of enzymic reactions: dielectric, electrostatic and steric stabilization of the carbonium ion in the reaction of lysozyme. , 1976, Journal of molecular biology.

[67]  T. Shinada,et al.  Stereospecific nucleophilic addition reactions to olefins. Addition of thiols to .alpha.,.beta.-unsaturated carboxylic acid derivatives , 1991 .

[68]  A. Ardizzoni,et al.  Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. , 2010, Journal of medicinal chemistry.

[69]  Massimiliano Bonomi,et al.  PLUMED: A portable plugin for free-energy calculations with molecular dynamics , 2009, Comput. Phys. Commun..

[70]  Ewa I. Chudyk,et al.  The basis for carbapenem hydrolysis by class A β-lactamases: a combined investigation using crystallography and simulations. , 2012, Journal of the American Chemical Society.

[71]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[72]  A. Ardizzoni,et al.  Epidermal growth factor receptor irreversible inhibitors: chemical exploration of the cysteine-trap portion. , 2011, Mini reviews in medicinal chemistry.

[73]  Yong Wang,et al.  P450 enzymes: their structure, reactivity, and selectivity-modeled by QM/MM calculations. , 2010, Chemical reviews.

[74]  Hua Guo,et al.  Antibiotic deactivation by a dizinc beta-lactamase: mechanistic insights from QM/MM and DFT studies. , 2007, Journal of the American Chemical Society.

[75]  M. Mor,et al.  Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors. , 2013, Journal of medicinal chemistry.

[76]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.

[77]  K. Merz,et al.  Catalytic mechanism of aromatic prenylation by NphB. , 2012, Biochemistry.